文献速递哮喘

重度哮喘患者严重急性发作率的国际差异

International Variation in Severe Exacerbation Rates in Patients With Severe Asthma.
PubMed 文献 · Chest · 2024-02-21

基于国际重度哮喘登记处17国7510例未用生物制剂的重度哮喘患者,随访365天观察严重急性发作率。粗发生率0.27/人年,各国间差异大(0.04至0.88),调整患者特征后仍显著(四分位距0.16-0.39),提示管理指南需考虑国家间差异。

要点

  • 重度哮喘严重急性发作率存在显著国家间差异,调整患者特征后仍明显。
  • 各国严重急性发作率范围0.04-0.88/人年,调整后四分位距0.16-0.39。
  • 疾病管理指南应认识并考虑国家间差异,风险预测模型需按辖区校准。

核心结论

  • 患者特征相似但来自不同辖区的重度哮喘个体,严重急性发作风险存在差异,即使控制患者和疾病特征后仍存在。
  • 这种差异提示存在未知患者因素或系统层面变异,疾病管理指南应认识到国家间变异性。
  • 需要针对每个辖区校准的风险预测模型以优化治疗策略。

研究设计与样本

  • 国际观察性队列研究,数据来自国际重度哮喘登记处。
  • 纳入年龄≥18岁、基线访视前未启用任何生物制剂的患者。
  • 严重急性发作定义为使用口服皮质类固醇≥3天或哮喘相关住院/急诊就诊。
  • 采用一系列负二项模型估计365天随访期间的国家特异性严重急性发作率,从仅含国家的朴素模型到以国家为随机效应项、患者和疾病特征为自变量的调整模型。
  • 最终样本包括来自17个国家的7510例患者(56%来自美国),贡献1939次严重急性发作(0.27/人年)。

主要发现

  • 观察到的严重急性发作率存在大国间差异:最低0.04(阿根廷),最高0.88(沙特阿拉伯),四分位距0.13-0.54。
  • 调整患者特征和抽样变异后,国家间差异仍然显著,四分位距为0.16-0.39。
  • 最终样本共7510例患者,来自17个国家,贡献1939次严重急性发作,总发生率为0.27/人年。

关键数值与推荐

  • 严重急性发作定义:使用口服皮质类固醇≥3天或哮喘相关住院/急诊就诊。
  • 纳入标准:年龄≥18岁,基线访视前未启用任何生物制剂。
  • 观察到的严重急性发作率范围:最低0.04(阿根廷),最高0.88(沙特阿拉伯),四分位距0.13-0.54。
  • 调整后严重急性发作率四分位距:0.16-0.39。

临床怎么用

  • 临床医生应意识到重度哮喘患者严重急性发作风险存在国家间差异,即使患者特征相似。
  • 疾病管理指南制定时应考虑国家间变异性,风险预测模型需按辖区校准以优化治疗策略。
  • 对于重度哮喘患者,评估急性发作风险时需考虑所在国家或地区的系统层面因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exacerbation frequency strongly influences treatment choices in patients with severe asthma. RESEARCH QUESTION: What is the extent of the variability of exacerbation rate across countries and its implications in disease management? STUDY DESIGN AND METHODS: We retrieved data from the International Severe Asthma Registry, an international observational cohort of patients with a clinical diagnosis of severe asthma. We identified patients aged ≥ 18 years who did not initiate any biologics prior to baseline visit. A severe exacerbation was defined as the use of oral corticosteroids for ≥ 3 days or asthma-related hospitalization/ED visit. A series of negative binomial models were applied to estimate country-specific severe exacerbation rates during 365 days of follow-up, starting from a naive model with country as the only variable to an adjusted model with country as a random-effect term and patient and disease characteristics as independent variables. RESULTS: The final sample included 7,510 patients from 17 countries (56% from the United States), contributing to 1,939 severe exacerbations (0.27/person-year). There was large between-country variation in observed severe exacerbation rate (minimum, 0.04 [Argentina]; maximum, 0.88 [Saudi Arabia]; interquartile range, 0.13-0.54), which remained substantial after adjusting for patient characteristics and sampling variability (interquartile range, 0.16-0.39). INTERPRETATION: Individuals with similar patient characteristics but coming from different jurisdictions have varied severe exacerbation risks, even after controlling for patient and disease characteristics. This suggests unknown patient factors or system-level variations at play. Disease management guidelines should recognize such between-country variability. Risk prediction models that are calibrated for each jurisdiction will be needed to optimize treatment strategies.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lee, Price, Yadav, et al. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma. Chest. 2024. PMID: 38395297. doi:10.1016/j.chest.2024.02.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。